Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
Steven David, Jennifer Tan, Peter Savas, Mathias Bressel, Dianne Kelly, Farshad Foroudi, Sherene Loi, Shankar Siva
The Breast | CHURCHILL LIVINGSTONE | Published : 2020
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an emerging noninvasive approach for the treatment of oligometastases. Limited prospective evidence is available in breast cancer. OBJECTIVES: To determine the safety and feasibility of single fraction SABR for patients with bone only oligometastatic breast cancer. Secondary endpoints were local and distant progression-free survival (LPFS and DPFS), toxicity and response assessment. METHODS AND MATERIALS: In this single institution prospective trial we screened patients with computed tomography, bone scan, and sodium fluoride positron emission tomography. Eligible patients had one to three bone only oligometastases. All patients w..View full abstract
Funded by a grant from the National Breast Cancer Foundation (NBCF) of Australia.